Psoriasis - adlimumab: appraisal consultation
The consultation period for this appraisal is 1 - 21 February 2008.
Psoriasis - adalimumab: appraisal consultation document
Psoriasis - adalimumab: appraisal consultation - pre-meeting briefing
Psoriasis - adalimumab: appraisal consultation - Evidence Review Group report
Psoriasis - adalimumab: appraisal consultation - Non-manufacturer submissions
Psoriasis - adalimumab: appraisal consultation - Manufacturer submission: Abbott Laboratories Ltd
Psoriasis - adalimumab: appraisal consultation - Expert written personal statements
This page was last updated: 30 March 2010